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Predicting and Monitoring Cancer Treatment
Response with Diffusion-Weighted MRI
Harriet C. Thoeny, MD1* and Brian D. Ross, PhD2
An imaging biomarker that would provide for an early
quantitative metric of clinical treatment response in can-
cer patients would provide for a paradigm shift in cancer
care. Currently, nonimage based clinical outcome metrics
include morphology, clinical, and laboratory parameters,
however, these are obtained relatively late following treat-
ment. Diffusion-weighted MRI (DW-MRI) holds promise
for use as a cancer treatment response biomarker as it is
sensitive to macromolecular and microstructural changes
which can occur at the cellular level earlier than anatomi-
cal changes during therapy. Studies have shown that suc-
cessful treatment of many tumor types can be detected
using DW-MRI as an early increase in the apparent diffu-
sion coefficient (ADC) values. Additionally, low pretreat-
ment ADC values of various tumors are often predictive of
better outcome. These capabilities, once validated, could
provide for an important opportunity to individualize
therapy thereby minimizing unnecessary systemic toxicity
associated with ineffective therapies with the additional
advantage of improving overall patient health care and
associated costs. In this report, we provide a brief techni-
cal overview of DW-MRI acquisition protocols, quantitative
image analysis approaches and review studies which have
implemented DW-MRI for the purpose of early prediction
of cancer treatment response.
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PATIENTS SUFFERING FROM a malignant tumor or
metastases undergo extensive therapies including
various side effects. Up to date treatment response is
evaluated by morphological, clinical, and laboratory
outcome. Radiological tumor response is based on the
extent of tumor size reduction as measured by ana-
tomical imaging modalities such as computed tomog-
raphy (CT) or MRI. However, therapy is typically deliv-
ered in fractionated doses, thus requiring sufficient
time for enough treatment to be delivered to kill cells
within the tumor as well as additional time needed for
immunological removal of the macromolecular debris.
Thus, therapy-induced changes in tumor volumes
often occur relatively late in the time course of
treatment.
Current therapeutic strategies in oncology include
surgery, radiation therapy, and chemotherapy, which
includes molecularly targeted agents against onco-
genic signaling pathways as well as vascular targets.
However, timely evaluation of treatment response in
patients undergoing radiation therapy or chemother-
apy, depending on the underlying pathology or treat-
ment strategy, is often very difficult. Evaluation of the
response to chemotherapy, based on changes in the
size of solid tumors, is typically evaluable after 6 to 8
weeks.
Development of antiangiogenic agents, and vascular
and molecularly targeted agents may not lead to sig-
nificant reduction in tumor size. Antiangiogenic
agents inhibit neovascularization of tumors, and vas-
cular targeting agents selectively destroy pathological
vessels without interfering with normal vessels.
Molecularly targeted agents for example, are directed
at oncogenic signaling molecules, which can for exam-
ple lead to a variety of biological effects including inhi-
bition of growth or apoptotic-induced cell death. In
2000, RECIST (response evaluation criteria in solid
tumors) defined the response to treatment in terms of
alteration of tumor size only (1). However, as newer
agents might provide therapeutic benefit by other
mechanisms than size reduction, new evaluation cri-
teria are of utmost importance. Recently, these
RECIST criteria were reconsidered and are consider-
ing imaging biomarkers such as positron emission
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tomography (PET) (2). In these articles, it has already
been considered that the up to date anatomic unidi-
mensional assessment of tumor burden has to be
changed to volumetric anatomical assessment as well
as functional assessment including PET and MRI.
Clinical assessment of new treatments in oncology
is evaluated by numerous response criteria, including
tissue and plasma biomarker readouts, improvement
in quality of life, and survival among others. As the
process to quantify response of agents undergoing
clinical trials may be lengthy, there is a significant
need for timelier outcome measures to be identified
and validated. The ability to quantify the effectiveness
of experimental therapies would significantly impact
the overall drug development process and offers the
potential of using DW-MRI to provide for early evalua-
tion and go, no-go decisions in phase 1 clinical trials
thus saving money and time. Thus early surrogate
indicators that correlate with long-term outcome met-
rics are urgently needed (3). Clinical trial measures
that could provide early readouts of drug-target inter-
actions and subsequent efficacy would facilitate quan-
tification of outcomes in clinical trials and ultimately
provide assistance in the regulatory approval process.
The current functional methods for response assess-
ment as suggested by RECIST 1.1 includes PET, PET-
CT, magnetic resonance spectroscopy as well as
dynamic contrast enhanced MRI. PET and PET-CT are
quite expensive methods and the differentiation
between residual tumor and inflammation is often
quite difficult using tracers such as [F18]fluorodeoxy-
glucose. Furthermore, radiation exposure is a draw-
back mainly in younger patients undergoing several
follow-up studies for response assessment. MR spec-
troscopy is a very promising method; however, its limi-
tations include low spatial resolution, restricted avail-
ability and lack of expertise of many radiologists.
Dynamic contrast enhanced MRI provides information
on changes in vascularization of the tumor during
treatment; however, image analysis is relatively com-
plicated and, therefore, not suited for daily clinical
routine. Furthermore, the risk of nephrogenic sys-
temic fibrosis—although being very small—has to be
taken into account in patients with renal insufficiency.
Diffusion-weighted MRI (DW-MRI) has not been con-
sidered in RECIST 1.1; however, this noninvasive MR
technique has been discussed as cancer biomarker in
a consensus meeting at the ISMRM 2008 and a publi-
cation on consensus and recommendations for DW-
MRI as a cancer biomarker has been published
recently highlighting the potential of this promising
technique in cancer patients (4).
DW-MRI for the evaluation of early treatment
response is very promising. As diffusion within
tumors is impeded by the presence of cellular mem-
branes and macromolecular structures, treatment
with for example radiation and/or chemotherapy can
result in the loss of cell membrane integrity, which
can be detected as an increase in mean diffusion
value for the tumor as shown in Figure 1. Thus, DW-
MRI can provide microstructural information on the
cellular level. Animal and clinical studies to date have
Figure 1. Schematic repre-
sentation of the relationship
between change in cellular
density following an effective
therapy and the correspond-
ing distribution of water diffu-
sion values within the tumor.
Note that the mean diffusion
value of a tumor increases
early following the loss of cel-
lular density. [Color figure can
be viewed in the online issue,
which is available at www.
interscience.wiley.com.]
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revealed that successful treatments of a wide variety
of tumor types can be detected as an increase in tu-
mor ADC values due to the loss of cellular density.
TECHNICAL REQUIREMENTS
Several technical requirements to perform follow-up
of cancer patients using DW-MRI have to be consid-
ered. Standardized techniques including patient prep-
aration for follow-up scans are important, e.g., when
evaluating the pelvis the filling of the urinary bladder
has to be taken into consideration. Parallel imaging
techniques offer several advantages for DWI, particu-
larly at high magnetic fields where magnetic field
inhomogeneity leads to large spatial distortion when
using single-shot EPI. Parallel imaging techniques use
previously acquired receiver coil sensitivity patterns
to reduce the quantity of phase-encode lines required
to reconstruct an image (5–7). This allows a shorter
single-shot echo train interval, thereby reducing inho-
mogeneity-induced phase accumulation manifest as
geometric distortion. There is a signal-to-noise ratio
(SNR) penalty associated with collecting fewer phase-
encode lines, but it can be offset by the SNR gain
achieved by the reduced minimum echo time afforded
by parallel imaging. Furthermore on the negative side,
parallel imaging may introduce artifacts characterized
by nonuniform noise and wrap-like artifacts that
occur at spurious locations within the field-of-view.
However, usually the benefits of parallel imaging
methods outweigh the drawbacks when applied to
single-shot EPI-based DW-MRI of the body. Therefore,
incorporation and trial of parallel imaging in these
protocols is encouraged, especially on 3 Tesla (T)
systems.
There are several options to reduce respiratory
motion artifacts when performing DW-MRI of the
chest and abdomen. When performing DW-MRI with
free breathing, multiple averaging is necessary to
increase SNR and reduce respiratory effects, although
this can lead to partial volume averaging and blur of
internal structures (8). Breathhold images are another
option, however, in cancer patients free breathing is
often easier to perform in severely ill individuals.
Even if the patient is able to hold his or her breath,
signal averaging within the breathhold interval is
severely limited, leading to low SNR. At the expense of
increased scan time, respiratory triggering or cardiac
gating may be used when performing DW-MRI in the
chest or upper abdomen. Although in a recent analy-
sis of motion control techniques it was noted that re-
spiratory-triggering yielded significantly higher ADCs
and lower ADC reproducibility than breath hold or
nonbreathhold scans (9,10). Anti-peristaltic agents
can be administered mainly when examining the
lower abdomen and the pelvis to avoid or minimize
bowel motion artifacts.
DW-MRI is usually performed in the three orthogo-
nal diffusion directions to minimize the influence of
anisotropy, although the degree of diffusion anisot-
ropy in non-neural tissues and tumor is relatively
low. By acquisition of DW-MRI in three orthogonal
directions, a rotationally invariant diffusion coefficient
can be calculated, that is, the diffusion measurement
is independent of the relative orientation of the tissue
architecture and gradient axes. Optimization of fat
suppression should also be considered. Presence of
fat signal in single-shot EPI DW-MRI is particularly
problematic because the apparent location of fat
structures are displaced many pixels along the phase-
encode direction thus may superimpose water-based
signals. This not only obscures the tissues of interest,
but also greatly distorts ADC measurement because
lipid protons have a very low diffusion coefficient.
Standard fat suppression techniques are applicable to
DW-MRI and include frequency-selection saturation of
fat signal, use of adiabatic pulses to reduce sensitivity
to B1 inhomogeneity in frequency-selection satura-
tion/inversion of fat, and nonfrequency selective
Short TI Inversion Recovery (STIR) methods that are
less affected by poor shim quality (11–13).
DW-MR images at a minimum of two sensitivity lev-
els defined by the sequence b-value must be acquired
to quantify ADC. Proper selection of b-values depend
on the given body DW-MRI application and objective.
The majority of clinical neuroimaging DWI studies
have been performed at b ¼ 0 and 1000 s/mm2 and
has grown acceptance as the default b-value set for
brain DW-MRI. However, microcirculation through
randomly oriented capillaries in the presence of diffu-
sion-sensitization gradients will also appear as a
hyper diffusion-like attenuation particularly in the
low b-value regimen (i.e., b ¼ 0 to 100 s/mm2). Cer-
tainly perfusion must be considered fundamentally
distinct from thermally driven diffusion, but perfusion
effects can be observed in DW-MRI particularly in vas-
cular-rich tissues/lesions thus should be considered
in design of DW-MRI protocols. Therefore, if one seeks
to disentangle perfusion effects from molecular diffu-
sion, additional b-values are required in the low b-
value range (0–100 s/mm2), which are sensitive to
perfusion effects, for contrast against nominal high b-
value decay, which is dominated by diffusion. The y-
intercept extrapolated from fitting signal decay versus
b-value using intermediate to high b-values compared
with the b ¼ 0 s/mm2 signal can be used as an esti-
mate of the perfusion signal component. Therefore,
collection of the b ¼ 0 DW-MRI (i.e., T2-weighted
image) is valuable to elucidate perfusion and diffusion
influences. Figure 2 illustrates this perfusion effect in
human kidney. Diffusion estimates are derived from
the exponential decay of DW-MRI signal versus b-
value. If a simple two-point estimate of signal decay is
used (as often is the case), then:





where b1 and b2 represent the low and high b-values.
By estimating ADC by means of the slope of log(signal)
versus b-value using b-values > 100 s/mm2, most of
the perfusion signal is attenuated leading to an ADC
estimate relatively free of perfusion contamination. At
high b-values, however, the signal may falsely exhibit
a multi-exponential shape due to the signal falling
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beyond the noise floor (see Fig. 2 for b ¼ 1000 to
2000 s/mm2). The maximum b-value should be set
such that signals recorded at that b-value are
adequately above the noise floor. This maximum b-
value depends on the SNR achievable for the target
organ/tissue and the water diffusion coefficient of
these tissues—the lower the diffusion value, the
higher the b-value achieved before the signal
approaches the noise floor. Tissues do exhibit true
multi-exponential diffusion decays over a wide b-value
range (b ¼ 500 to > 3000 s/mm2), although very high
SNR is required to document these features (14).
IMAGE ANALYSIS
To evaluate DW-MRI, there are two general categories
for image analysis: qualitative and quantitative. More-
over, the ‘‘image’’ may represent several quantities
derived from DW-MR images. For example, ADC maps
may be calculated over a specified b-value range, the
image may represent an anisotropy index derived
from a series of multiple directions of DW-MR images,
or the image may represent an index that quantifies
the multiexponential features of the diffusion decay
over a wide range of b-values.
Shown in Figure 3 are a series of liver images
acquired with varying b-values of 0, 100 and 600 s/
mm2. Note the heavily T2-weighted contrast at b-value
of 0 s/mm2 which includes bright vascular signal.
The vascular signal is greatly attenuated at moderate
diffusion weighting of 100 and 600 s/mm2. Calcu-
lated ADC maps derived from the low b-value data (0
and 600 s/mm2) yield ADC maps highly influenced by
flowing blood. Use of moderate to high b-values (b ¼
100 to 600 s/mm2) provide a more accurate measure
of water diffusion free of vascular contamination (Fig.
3).
In general, water diffusion in tissue may be aniso-
tropic; that is directionally dependent on the natural
underlying directionality of cellular elements that
impede water mobility. Neural tissue in particular is
highly anisotropic where the diffusion coefficient may
vary several-fold dependent on the relative orientation
of the diffusion encoding gradient and the tissue
structure. Most non-neural tissue exhibit nearly
Figure 2. Measured signal decay in kidney cortex of as a function of b-value. Perfusion effect is dominant in the low b-value range
(0–100 s/mm2) and would inflate ADC if included in slope calculations. By extinguishing most of the vascular signal at b values
greater than 100 s/mm2, a true estimate of ADC is derived. Using b-values 100 to 750 s/mm2, the estimated kidney ADC ¼ 2.03
 103 mm2/s. The dashed line represents the noise floor. DW-MRI measurements where signal falls within the noise floor lead to
erroneous ADC estimates and a false multi-exponential appearance to the log(signal) versus b-value curve. Tissues do exhibit true
multi-exponential diffusion decays over a wide b-value range (b ¼ 500 to > 3000 s/mm2), although very high SNR is required to
document these features. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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isotropic water diffusion; although in general one
should not assume tissue is isotropic when perform-
ing diffusion measurements. Diffusion encoding
should be performed along at least three orthogonal
gradient directions to properly account for possible
anisotropy.
QUALITATIVE ASSESSMENT
The signal intensity change during treatment can be
assessed by visual analysis of the underlying pathol-
ogy as shown in Figure 4. In this example of a patient
with two distinct hepatocellular carcinomas treated
with transarterial chemoembolization (TACE), the
solid tumors before treatment on a high b-value image
show high signal intensity while the corresponding
ADC maps exhibit low signal intensity. During suc-
cessful treatment, the loss of cellularity in the upper
tumor resulted in the high b-value image to shift to-
ward lower signal intensity or high signal intensity on
the corresponding ADC map. Although these are early
changes, formation of fibrosis in the extracellular ma-
trix can also occur later on during therapy and in
some types of tumors if this occurs, it would result in
low signal intensity on the high b-value image and on
the corresponding ADC map. Posttherapeutic changes
such as edema during radiation therapy demonstrate
high signal intensity on the high b-value image as
well as on the corresponding ADC map. An additional
issue arising when using b-images as the singular
image to base disease or treatment response assess-
ment is the ‘‘T2 shine-through’’ effect. This effect can
result in a tissue region appearing to exhibit higher
signal intensity on b-images in the range of 500–1000
s/m2 due to complicating factors such as the long
intrinsic T2-relaxation time of the tissue. Avoidance of
mis-interpretation of images due to artifactual T2-
shine through effects can be accomplished by com-
parison with the corresponding ADC map.
QUANTITATIVE ASSESSMENT
In general, advancement of a biomarker must be dem-
onstrated in multicenter trials with standardized ac-
quisition techniques and with appropriate quality
control (QC) standards to provide quantitative agree-
ment across systems and assess overall repeatability.
These quality issues require investigators to agree
upon an appropriate QC phantom. A specific phantom
for this purpose has not been decided upon by the
broader community, although phantoms for DW-MRI
have been proposed (15,16). Recent consensus has
been reached as to a variety of issues by a consortium
of investigators brought together by the National Insti-
tutes of Health to form overall recommendations (4).
Quantification of diffusion properties as a potential
early surrogate response metric of clinical efficacy is
commonly accomplished. There are two primary
approaches to perform quantitative analysis of DW-
MRI derived maps: (i) change in mean ADC value over
the entire tumor or select spatial zones of the tumor,
and (ii) a voxel-by-voxel change in ADC maps or other
diffusion parametric maps.
In oncologic imaging applications, these two areas
are particularly noteworthy to assess treatment
response. The two distinct approaches involved in
quantitative analyses of tumor ADC changes men-
tioned above are highlighted in the discussion below.
CHANGE IN ADC FOLLOWING THERAPY
This is a simple method that uses the whole tumor
average ADC value where an increase in ADC follow-
ing therapy due to a decrease in cellularity suggests a
positive therapeutic response (Fig. 1) (17,18). This
approach has been widely used in animal tumor stud-
ies where tumor treatments are very effective and tu-
mor cell lines tend to be more responsive to interven-
tions and in a shorter time span than is observed
clinically (17,19–30). Moreover, extracting ADC values
from ADC maps by drawing regions of interest around
the margin of the tumor is relatively simple to per-
form. The resultant distribution of ADC values are
typically plotted in a histogram format and the mean
or median value is used to evaluate changes following
treatment over time. However, histogram-based detec-
tion of treatment-induced diffusion changes can be
attenuated if spatially varying diffusion values occur
Figure 3. Effects of b-values on blood flow contribution to
images and ADC maps. DW-MRI of the liver with b-values of
0, 100, and 600 s/mm2 (center column) revealing suppres-
sion of vascular signal with increasing b-value. ADC maps
generated using b-value images of 0 and 600 s/mm2 as well
as 100 and 600 s/mm2. ADC maps generated using b-values
of 100 and 600 s/mm2 have attenuated contribution/con-
tamination from perfusion effects (right ADC map) compared
with the ADC map generated using b-values of 0 and 600 s/
mm2. [Color figure can be viewed in the online issue, which
is available at www.interscience.wiley.com.]
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wherein both an increase and a decrease occur within
the tumor. In this situation, competing factors would
reduce the mean shift in ADC using a histogram-
based approach. Furthermore, if large cystic or ne-
crotic regions are present within the tumor mass,
these would also have the potential to reduce detecta-
ble changes in tumor ADC values following treatment
as they would ‘‘weight’’ the number of unchanged val-
ues according to their proportion of the total voxels
thus reducing the overall net change in ADC value.
Therefore, the histogram-based approach for detection
of treatment response can be attenuated by pre- and
posttreatment spatial heterogeneity within the tumor.
PARAMETRIC RESPONSE MAP ANALYSIS
In an effort to address the effects of spatial heteroge-
neity within the tumor mass, a voxel-by-voxel
approach was proposed (31). This voxel-based
approach spatially registered the pretreatment ADC
map to a posttreatment initiation ADC map to provide
for quantification of diffusion changes on the voxel
level. Using this approach, changes in individual vox-
els can be tested for significance and superimposed
on anatomic maps to reveal the spatial information
within the context of the three-dimensional view of
the tumor. ADC changes are encoded as color maps
and overlaid on the anatomical MRI to obtain spatial
information. This approach provides for the possibility
of also guiding the therapist in adapting therapy early
as well as assisting in the ability to spatially guide a
directed therapy approach. The voxel-based analytical
method was termed the functional diffusion map
(fDM) and more recently the parametric response map
(PRM) as it allows for quantification of the relative
area or percentage of tumor volume in which signifi-
cant change had occurred as the response metric (ei-
ther a decrease or increase in ADC values) (Fig. 5).
Shown in Figure 5, changes in tumor cellular struc-
tures can occur due to an apoptotic cell death pro-
cess, which would result in the decrease in tumor cel-
lularity thus causing an increase in tumor ADC
values in those regions. Swelling of tumor cells would
produce a drop in ADC values transiently, which
upon conversion to necrosis, would produce an ele-
vated ADC value. Image registration of pretreatment
ADC maps with a follow up ADC map acquired follow-
ing treatment initiation allows for presentation of the
PRMADC data both in terms of a three-color overlay
where red indicates increased ADC values, blue
decreased ADC values and green unchanged ADC val-
ues as shown in Figure 5. These data can also be
shown as a scatter plot and quantification of changes
presented as a percent of tumor voxels (i.e., volume)
with increased ADC values (Fig. 5). This technique is
readily applied in tumor sites where tumor growth is
modest and tumors can be spatially registered with
well established algorithms such as the affine trans-
form. Extension of PRM to monitoring of tumors
located at other sites where tumor growth and/or sur-
rounding tissues are more elastic can be implemented
using nonlinear warping algorithms for image regis-
tration (32).
Applications of PRMADC tumor treatment response
monitoring have been reported in both animal and
clinical studies. Correlation of increased PRM values
following treatment in a brain tumor glioma model
Figure 4. A patient with a he-




(top row) pre and (bottom row)
posttherapy. Each set of
images consists of the DW-
MRI (left images) along with
their corresponding color ADC
overlay maps (right column).
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revealed that measurement of early changes at 4 days
after treatment of the PRMADC metric correlated with
overall survival in a dose-response chemotherapy
study (33). This animal study validated the PRM
imaging biomarker as an early response predictor for
animal studies. Several clinical studies have also been
reported in grade III/IV glioma patients (31,34,35)
and in head and neck tumor patients (32). Overall,
these clinical studies have reported correlation of
early PRMADC changes with late, traditional clinical
outcome measures revealing the potential utility of
this voxel-based approach as an imaging oncologic
response biomarker. Finally, extension of the voxel-
by-voxel analysis approach has been reported using
MRI perfusion maps from brain tumor patients
undergoing therapy wherein changes as early as 1
week into therapy could be used to predict patient
outcome (36). This study reveals that the voxel-by-
voxel approach may provide improved sensitivity for
treatment response assessment for a broad range of
imaging modalities which includes DW-MRI.
MULTIEXPONENTIAL DIFFUSION/PERFUSION
PROPERTIES OF TREATED TUMORS
The signal loss in DW-MRI with increasing b-value
does not necessarily follow a monoexponential decay
(37). The perfusion component of tissue appears as a
‘‘hyper diffusion-like’’ decay with b-value over the low
b-value regimen (0–100 s/mm2). At higher b-values
(>100 s/mm2), the perfusion signal is largely extin-
guished, thus, ADC measurements are more heavily
influenced by the water diffusion properties within
the cellular matrix. The apparent diffusion coefficient
provides us information on diffusion and perfusion
provided that these two entities can be separated.
In an experimental study in rats, DW-MRI was per-
formed for monitoring the effect of a vascular target-
ing agent on rhabdomyosarcomas (38). As vascular
targeting agents selectively destroy pathological ves-
sels the aim of the study was to perform DW-MRI to
detect changes in diffusion and perfusion noninva-
sively and without contrast medium administration.
For that reason, three different ADC values were cal-
culated out of a large series of b-values: to approxi-
mate true diffusion an ADC was calculated only out of
high b-values (500, 750, 1000 s/mm2 ¼ ADChigh). An
ADC including b-values from 0 to 100 s/mm2 (perfu-
sion and diffusion) was considered as ADClow,
whereas the difference between ADClow and ADChigh
was hypothesized to approximate perfusion. In addi-
tion, when ADC is used, it is assumed to mean from
values generated using b-values between 0 and 1000
s/m2.
In this study performed on rhabdomyosarcomas in
rats, imaging was performed before administration of
this vascular targeting agent, 1 h, 6 h, 2 days, and 9
days after start of therapy, where morphological
images, including images before and after contrast
medium administration as well as DW-MR images
were performed during treatment and histopathologi-
cal correlation at each time point were presented (38).
One hour after vascular targeting injection leading
to disruption of the pathological vessels, no perfusion
of the solid tumor could be detected. However, the
corresponding ADC map still showed vital tumor cells
reflected as a low signal intensity of the solid tumor
confirmed by histology. Similar findings were
observed 6 h after injection of the vascular targeting
Figure 5. (Left panel) Diagrammatic representation of two possible pathways of cell death associated with therapy. Induction
of apoptosis which would lead to an increase in tumor ADC values due to cell shrinkage and loss of cellular density. Proc-
esses involved with the induction of necrosis which might exhibit a transient initial drop in ADC values due to cell swelling
following by an increase in ADC values during cell lysis during the later stages of this death pathway. (Right panel) The
voxel-by-voxel analytical approach (functional diffusion map [fDM] or parametric response map [PRMADC]) used to quantify
diffusion changes following therapy within a tumor using ADC maps pre- and posttreatment initiation. (Used with permis-
sion. Moffat BA, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratifi-
cation of clinical brain tumor response. Proc Natl Acad Sci USA 2005;102:5524–5529. Copyright (2005) National Academy of
Sciences, USA).
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agents. The reason for the lack of enhancement as
seen on conventional postcontrast T1-weighted fat
saturated images was determined to be vasoconstric-
tion and vasocongestion, which was identified on his-
tological tumor sections. Only 2 days after therapy,
the morphological images showing necrosis corre-
sponded to tumor death on the ADC map, which was
also confirmed histologically. Nine days after treat-
ment, the tumor started regrowing from the periphery
as seen on morphological images, the same results
were also seen on ADC maps and corresponding his-
tological specimens.
When measuring the ADC values early after treat-
ment (1 and 6 h), a decrease in ADChigh was seen and
attributed to cell swelling and consequent impeded
diffusion in the extravascular space. The decrease in
perfusion was due to vascular shutdown. During true
necrosis at 2 days, the ADChigh increased, whereas
ADChigh during relapse decreased again due to
increase in cellularity of the tumor. In another study,
the difference between ADClow and ADChigh as sug-
gested corresponding to perfusion was correlated with
the volume transfer constant k calculated from
dynamic contrast enhanced images during follow-up
of treatment. A correlation between these two parame-
ters calculated from these two different techniques
was demonstrated, suggesting that dynamic contrast
enhanced MRI provided information on perfusion
changes during treatment, whereas DW-MRI was able
to provide information on perfusion changes and also
allowed for differentiation between viable and necrotic
regions within the tumor mass (39).
As it has already been suggested by Le Bihan, sepa-
ration of diffusion and perfusion in intravoxel inco-
herent motion MR imaging should be performed and
this was reconsidered in a recent paper published in
Radiology from the same author (40). As many treat-
ment strategies lead to changes on different levels of
the tumor, the differentiation between diffusion and
perfusion calculated from the DW-MR images might
help to provide information on additional and more
subtle changes that might occur during treatment.
DW-MRI AS BIOMARKER
DW-MRI as biomarker has several advantages
because it provides microstructural changes related
to treatment effects over time that usually precede
change in size. No ionizing radiation and no injection
of isotope or any other contrast medium is necessary.
Furthermore, the acquisition time to perform DW-MRI
lasts only a few minutes, the method is easily repeat-
able providing quantitative information and informa-
tion on spatial distribution including heterogeneity of
the tumor and its response. In addition, this tech-
nique is magnetic field independent and, therefore,
multicenter and longitudinal studies can be per-
formed easily.
Early detection of treatment response might change
therapeutic strategies in case of nonresponders to
avoid toxicity and other negative side effects; it might
allow individualizing treatment and hopefully increase
long-term survival. In addition, money for ineffective
treatment can be saved. DW-MRI in oncology has sev-
eral key applications including diagnosis, tumor stag-
ing, and early evaluation of treatment response and
detection of relapse.
DW-MRI for monitoring therapy has already been
applied in a wide variety of cancer types and organ
sites, including the liver, breast, bone, soft tissue
tumors, cervical tumors, head and neck tumors, as
well as rectal cancer (41–65).
CLINICAL APPLICATIONS OF DW-MRI FOR
MONITORING TREATMENT RESPONSE
IN DIFFERENT ORGAN SITES
Liver Metastases
Hepatic metastases are the most common neoplasms
in the liver. Only selected lesions can be surgically
resected, therefore, the vast majority of tumors are
treated by chemotherapy. Size reduction as ultimate
response to successful treatment often occurs rela-
tively late; hence, early detection of response based
on DW-MRI findings would be helpful to avoid
unnecessary treatment in case of therapy failure. Sev-
eral articles already showed that systemic chemother-
apy of liver metastases had a good correlation of
response with increased ADC values following treat-
ment (28,47,48).
In a study that has been performed in 2004 in
patients with liver metastases from breast cancer, a
correlation between ADC changes and tumor reduc-
tion was found at 4 and 11 days after start of therapy.
The authors concluded that DW-MRI could be used to
predict the response of liver metastases to effective
chemotherapy (28). Similar results were reported in a
study of 20 patients with potential operable hepatic
lesions larger than 1 cm in diameter metastatic from
colorectal carcinoma. In this study, quantitative ADC
maps were calculated separately with b-values from 0
to 500 and with b-values from 150 to 500 s/mm2.
The nonresponding lesions had a significantly higher
pretreatment mean ADC (ADC 0–500 and mean ADC
150–500) than did responding lesions. After chemo-
therapy, responding lesions had a significant increase
in ADC, whereas no significant change was observed
in nonresponding metastatic lesions after chemother-
apy (47). The authors conclude that high pretreatment
mean ADC values of liver metastases from colorectal
cancer were predictive of poor response to chemother-
apy. Responding lesions showed a significant increase
in mean ADC in contrast to nonresponding lesions,
indicating the potential of this method for the develop-
ment of individualized therapy. These results were
confirmed by a recent study performing DW-MRI as a
potential imaging biomarker for prediction and early
detection of response to chemotherapy in a total of 87
liver metastases (from colorectal and gastric carcino-
mas). The pretreatment mean ADCs5 in responding
lesions were significantly lower than those of nonres-
ponding lesions (P ¼ 0.003). An early increase in ADC
(on day 3 and 7) was observed in responding lesions
in contrast to nonresponding lesions (P ¼ 0.002),
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preceding the effects of change in size that was only
possible at a later time point. The authors concluded
that ADC seems to be a promising tool for helping to
predict and monitor the early response to chemother-
apy of hepatic metastases from colorectal and gastric
carcinomas (48).
In 12 patients with 48 metastatic liver lesions from
colorectal cancer, DW-MRI was applied for the evalua-
tion of therapeutic response to hepatic arterial infu-
sion chemotherapy (HAIC) with 5-fluorouracil (49).
Imaging was performed before and 9 days after HAIC.
Positive correlations were observed for relative change
between %min ADC and reduction ratio (r ¼ 0.709)
and between %mean ADC and reduction ratio (r ¼
0.536). Both parameters (%min ADC and %mean
ADC) were significantly greater in the responder group
than in the nonresponder group as evaluated on fol-
low-up CT after 3 months. These results show the
usefulness of DW-MRI for early detection of response
of liver metastases undergoing treatment with HAIC.
Malignant Liver Lesions
In recent years interventional techniques such as
TACE and hepatic radiofrequency (RF) ablation gained
importance in the curative or palliative treatment of
hepatocellular carcinoma (HCC) or of liver metastases.
The early assessment of successful treatment or
relapse is important in patient management; however,
the differentiation between residual or recurrent tu-
mor from nontumoral tissue changes following ther-
motherapy or chemoembolization is a challenging
issue when applying conventional techniques includ-
ing CT or MRI.
Navigator respiratory-triggered DW-MRI in the fol-
low-up of hepatic RF ablation in 54 patients with 77
liver lesions (17 primary tumors, 60 metastases due
to different underlying tumors in 37 patients) showed
promising results in the detection of local tumor pro-
gression compared with nontumoral posttreatment
tissue changes (50). Hyperintensities in the periphery
of the ablation zone of the tumor on DW-MR images
on 58 of 148 examinations corresponded to local tu-
mor progression confirmed by follow-up in only 17 of
these lesions, whereas the remaining signal altera-
tions disappeared during follow-up. However, when
performing quantitative analysis of these suspicious
hyperintense areas on the corresponding ADC map
the ADC values were significantly lower in case of
local tumor progression than in cases without tumor
progression (102.1 6 22.4 versus 130.8 6 47.6 
105 mm2/s; P ¼ 0.00124), suggesting the potential
of DW-MRI in this particular setting.
In 24 patients with unresectable HCC undergoing
TACE, contrast-enhanced MRI and DW-MRI were per-
formed before, 24 h, and 1, 2, 3, and 4 weeks after
therapy (51). Mean tumor size was unchanged up to 4
weeks after TACE, whereas reduction in tumor
enhancement in the arterial and portal venous phase
occurred immediately after therapy with a consistent
reduction in the first 3 weeks. The increase in tumor
ADC value was significant 1–2 weeks after therapy (P
¼ 0.004), borderline significant after 3 weeks, and in-
significant after 24 h and 4 weeks after therapy. In
another study in 23 patients with 26 HCCs treated
with TACE, DW-MRI improved the sensitivity of DCE-
MRI (85% to 92%) in the detection of peri-lesional tu-
mor recurrence; however, its specificity decreased
from 65% to 50% after adding DW-MRI (52). In this
study, b-values of 50, 400, and 800 s/mm2 were
applied. As biexponential fitting provides more
detailed information on perfusion and diffusion
changes separately, this technique might be helpful in
this particular setting were perfusion changes are
expected to appear; however, this can only be done on
the expense of longer imaging times.
Overall the utility of DW-MRI for monitoring treat-
ment response in HCC and metastases is very promis-
ing and may provide the possibility of individualizing
treatments for this population of patients.
Pancreatic Cancer
As pancreatic cancer is often diagnosed at an
advanced stage, a curative surgical approach is often
too late and chemotherapy or chemoradiotherapy are
the only treatment options. The stratification of res-
ponders and nonresponders at an early stage after
initiation of treatment might allow to change or stop
therapy avoiding the high risk of complications and
side effects and ultimately save unnecessary expenses
for useless treatments.
In a recent study, a consecutive group of 63
patients with advanced pancreatic cancer who were
treated with chemotherapy underwent DW-MRI before
therapy and follow-up was performed by CT (53). The
patients were classified into two groups according to
the findings during follow-up: (a) those with progres-
sive disease and (b) those with stable disease at 3 and
6 months after initial treatment. DW-MRI was applied
using three b-values (0, 400, and 1000 s/mm2), and a
middle (including a b-value of 400 s/mm2) and high
(including a b-value of 1000 s/mm2) ADC were calcu-
lated in the solid parts of the tumor. The results of
this study showed that the rate of tumor progression
was significantly higher in those with a lower high b-
value ADC than in those with a higher b-value ADC.
The authors concluded that a lower high b-value ADC
in patients with advanced pancreatic carcinoma may
be predictive of early progression in chemotherapy-
treated patients. Of interest, these findings are con-
tradictory to liver metastases where a low pretreat-
ment ADC value was correlated with better outcome
after treatment (47,48), however, similar to findings
reported in rectal cancer (43,54). In pancreatic can-
cers, a low ADC corresponding to early progression
might be attributed to a high cellularity with conse-
quent higher aggressiveness of the tumor but due to
the worse response might probably be related to des-
moplastic reaction in the tumor before treatment.
Breast Cancer
Neoadjuvant chemotherapy in patients with breast
cancer is a relatively controversial issue; however, this
treatment is helpful to reduce size of the tumor before
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surgery with a consequent improved rate for breast
conserving surgery. DW-MRI is ideal for monitoring
treatment response, because the results can be corre-
lated with histology. In responding primary breast
cancers, increased ADC values have been reported.
Changes in ADC after the first cycle of chemotherapy
significantly correlated with volume and diameter
(42,55). The pretreatment ADC values in a study
including a control group, the contralateral normal
breast as well as benign lesions and malignant lesions
before therapy, were lowest in the malignant breast
lesions compared with all the other groups. A change
in ADC after the first cycle was statistically significant
compared with volume and diameter at the end of
treatment indicating the potential in assessing early
response. It has been concluded, that the results of
this study show that the ADC is more useful for pre-
dicting early tumor response to new adjuvant chemo-
therapy than morphological variables suggesting its
potential in effective treatment management (42).
In a breast cancer human xenograft model treated
with chemotherapy, the mean change in tumor ADC
values was found to be significantly increased by 44%
at day 4 after therapy (56). The increase in ADC val-
ues was correlated with both activation of apoptosis
and presentation of cell death within the tumor mass
in this study. More recently a study was performed in
breast tumor xenografts with applied DW-MRI (9.4T,
b-values of 5 and 1000 s/mm2) to apoptosis-inducing
anti-DR5 antibody. In this experimental study per-
formed on nude mice bearing luciferase-positive
breast tumors, the effect to increasing doses of treat-
ment was evaluated at different time points. The
mean ADC increase was linearly proportional to the
mean apoptotic cell density, whereas the tumor vol-
ume changes were not different at day 3 after treat-
ment in contrast to the ADC increase. The analysis of
the peripheral shell of 1 mm from the outer surface
eliminated the ADC increase resulting from central tu-
mor necrosis, improving the specificity of ADC quanti-
fication. In this study, DW-MRI as early imaging bio-
marker for effective apoptosis-induction therapy has
been shown in a preclinical breast cancer model (57).
Therapeutic efficacy of the apoptosis-inducing strat-
egy was detected as early as 3 days after increased
dosing by using ADC quantification at the time when
tumor volume changes were not apparent. An
improved method of using the ADC data was demon-
strated by using analysis of the peripheral shell of the
tumor instead of analysis of the entire tumor region.
ADC increases in tumor were dose dependant and
were persistent with histological markers of apoptosis.
The mean ADC increase in tumors was linearly pro-
portional to the mean apoptotic cell density and was
inversely proportional to the mean proliferating cell
density. Optimizing the time point of imaging after
start of treatment is crucial to maximize the accuracy
of measuring therapeutic response (57). Based on
these data, there is potential in the future to optimize
patient therapy on the basis of DW-MRI to monitor
effective response at an early interval after initiation
of therapy and to prevent unnecessary treatment and
establishing individualized therapeutic strategies.
This study was performed on a 9.5T MR unit using b-
values of 5 and 1000.
Another recently published animal study performed
in mice with BT474 breast tumor xenografts analyzed
different MRI methods for evaluating the effects of dif-
ferent treatment regimens with tyrosine kinase inhibi-
tor gefitinib (58). Tumor volume, ADC, transendothe-
lial permeability (Kps), and fractional plasma volume
(fPV) were measured in three groups receiving (a) con-
trol animals for 10 days, or gefitinib as (b) a single
daily dose for 10 days or (c) a 2-day pulsed dose. A
significant tumor growth delay (pulsed: 439 6 93;
daily: 404 6 53; controls: 891 6 174 mm3; P < 0.050)
and lower cell density (P < 0.050) were observed 9
days after treatment with gefitinib. Tumor ADC
increased in treated groups but decreased in controls
(P > 0.050). Tumor Kps decreased with pulsed treat-
ment at day 4, but increased afterwards, from base-
line to day 9 in the daily dose group and decreased in
the control group 9 days after therapy. Tumor fPV
increased in both treated groups, with a decrease
afterwards with pulsed treatment (P > 0.050). The
authors of this animal study concluded that quantita-
tive MRI can provide sensitive information as to tyro-
sine kinase inhibitor-induced tumor changes, sug-
gesting the potential of distinguished treatment
regimens and ultimately helping in the determination
of optimal treatment scheduling for enhancing chemo-
therapy delivery.
Bone and Soft Tissue Tumors
The response to therapy in bone tumors has been per-
formed by qualitative analysis looking at the signal in-
tensity changes of bone marrow after therapy as well
as by quantitative analysis measuring the ADC val-
ues. In 24 patients with spine metastases, DW-MRI
and spin-echo MRI was performed before and after
radiotherapy. Treatment response has been evaluated
by qualitative analysis looking at the signal intensity
changes of bone marrow after therapy (59). Metasta-
ses before radiotherapy showed a hyperintense signal
intensity on the images at a b-value of 165 s/mm2
applied in one direction. A signal decrease 1 month
after therapy was defined as response to therapy. In
23 of 24 patients, hypointense signal intensity after
successful treatment could be detected, whereas 1 of
24 patients showed persistent hyperintense bone
marrow corresponding to no clinical improvement.
The authors concluded that DW-MRI allows detecting
decreased signal intensity in metastatic disease to the
vertebral body marrow corresponding to successful
treatment.
In 18 osteogenic and Ewing sarcomas, monitoring
of therapeutic response of primary bone tumors has
been performed by using DW-MRI. ADC measure-
ments were performed before and 10 to 14 days after
finishing chemotherapy. Definitive surgery was per-
formed within 3 days after the postchemotherapy MR
study. Necrosis was evaluated on histology. Signifi-
cantly greater ADC change was observed in the group
with tumor necrosis of more than 90% compared with
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the group with less than 90% necrosis on histology
after treatment. However, no statistical significant dif-
ference in tumor volume between the two groups
could be detected. Therefore, the ADC value of DW-
MRI could be used as a promising tool for monitoring
the therapeutic response to primary bone sarcomas
(41). In a preclinical model of metastatic prostate can-
cer, the fDM as an imaging biomarker for assessing
early treatment response has been evaluated to quan-
tify especially distinct therapy-induced changes in the
Brownian motion. In contrast to control animals, a
significant increase in ADC could already be detected
early after treatment. The results of this study have
shown the possibility of functional diffusion maps as
a biomarker for the detection of bone cancer treat-
ment efficacy with the aim to switch to an alternative
therapy in a timelier manner in case of ineffective
therapy (60).
These results were confirmed in a patient with met-
astatic prostate cancer to the bone where DW-MRI
was performed at the start of therapy and 2 and 8
weeks after treatment initiation to quantify changes in
tumor diffusion values. In all three metastatic lesions
that were analyzed, an early increase in diffusion val-
ues at 2 weeks which increased further at 8 weeks af-
ter treatment initiation could be observed correlating
with the decrease in the patients prostate-specific
antigen levels suggestive of patient response.
Although this has been shown in only one patient, the
fDM imaging biomarker may provide a quantifiable
therapeutic end point to assess response to patients
with metastatic bone cancer (61).
DW-MRI also resulted as useful noninvasive method
to monitor anticancer treatment effects in 23 consecu-
tive patients with soft-tissue sarcomas (44). DW-MRI
was performed before and after initiation of chemo-
therapy. A high degree of correlation was found com-
paring changes in tumor volumes and ADC values (r
¼ 0.925; P < 0.0001), regardless of the effectiveness
of anticancer treatment expressed as changes in tu-
mor volume. As microstructural changes evaluated by
DW-MRI are expected to precede change in tumor size
and volume, DW-MRI performed at an early stage of
fractionated therapy might provide unique prognostic
information of effectiveness (44). An example of DW-
MRI results obtained following chemotherapy of a
patient with a soft tissue sarcoma is shown in Figure 6.
In this example, a color ADC map is shown before
therapy with a whole tumor average ADC value of
1.58  103 mm2/s. At 3 weeks into chemotherapy,
the mean ADC value for the sarcoma increased by
15.2% to a value of 1.82  103 mm2/s, which is
clearly evident from the color overlay maps (see
arrows in Fig. 6) indicating a positive response to
therapy which was clinically observed for this
patient.
Head and Neck Cancer
In head and neck cancer, early evaluation of treat-
ment response may provide prognostic information
about treatment efficacy and subsequent tailoring of
treatment based on individual response might follow
(62). DW-MRI as an imaging biomarker of treatment
response of squamous cell head and neck cancer has
been evaluated in a mouse model undergoing treat-
ment with chemotherapy, ionizing radiation and com-
bined therapy compared with control animals. The
animals were examined during and after treatment for
changes in tumor volumes, diffusion values, and sur-
vival (63). Radiation therapy had only minimal effect
on volumetric growth rate diffusion and survival
whereas a combination of chemotherapy and radio-
therapy showed an increase in tumor diffusion values
which correlated with improved survival. The authors
of this animal study concluded that DW-MRI as an
imaging biomarker has the potential for early evalua-
tion of the response to chemoradiation treatment in
squamous cell carcinoma of the head and neck (63).
There is one study performed in 40 patients with
newly diagnosed head and neck cancer which per-
formed DW-MRI before, during, and after chemoradia-
tion therapy of head and neck metastases to lymph
nodes. In this study, 33 patients with head and neck
squamous cell carcinoma and metastatic cervical
Figure 6. Patient with a soft tissue sarcoma. (Left) Pretreatment high b-value image shows revealing large dense (fibrosis)
region on the lower left along with a high cellular region. ADC color overlay maps of the sarcoma (Middle) before and (Right) 3
weeks following chemotherapy. Note that the tumor mass (arrow) exhibited a large increase in tumor ADC values following
treatment indicating positive response. (Image kindly provided by T.L. Chenevert, University of Michigan). [Color figure can
be viewed in the online issue, which is available at www.interscience.wiley.com.]
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lymph nodes were included and the analysis of ADC
values in metastatic lymph nodes were measured
before, 1 week after start of chemoradiation therapy,
and posttreatment (46). The pretreatment ADC values
of complete responders (1.04 6 0.19  103 mm2/s)
were significantly lower than those from partial res-
ponders (1.35 6 0.30  103 mm2/s). In complete
responders, significant increase in ADC was observed
within 1 week of treatment, which continued until the
end of treatment. Furthermore, a significantly larger
increase in ADC values was found in complete res-
ponders as compared to partial responders by the first
week of chemoradiation. The results of this study
were quite interesting; however, the ADC values were
measured in the metastatic lymph nodes and not on
the primary site which would be more challenging
and also very helpful for daily decision making in clin-
ical routine. However, the authors of this study con-
cluded that the results suggest that ADC can be used
as a marker for prediction and early detection of
response to concurrent chemoradiation therapy in
head and neck squamous cell carcinoma (46).
In a recent study, PRMADC was evaluated as an
imaging response biomarker in head and neck cancer
patients at 3 weeks after initiation of nonsurgical
organ preservation therapy (NSOPT) (32). A total of 15
patients were studied in which primary site as well as
metastatic lymph nodes were evaluated. Shown in
Figure 7 are PRMADC examples of two different
patients who were subsequently found to have differ-
ent clinical responses to NSOPT. The patient with the
most robust therapeutic response exhibited a much
larger shift in the overall number of increased ADC
voxels at 3 weeks following treatment initiation (Fig.
7A) versus the comparative patient (Fig. 7B). In this
study the degree of PRMADC shift exhibited by individ-
ual patients at 3 weeks was found to correlate with
tumor control at 6 months. This study reveals the fea-
sibility of using voxel-based assessment of tumor dif-
fusion changes in patients where nonlinear warping
Figure 7. Representative slices of PRMADC for patients whose conditions were diagnosed as (A) complete response (CR) and
(B) partial response (PR); color-coded volumes of interest are shown as overlays on contrast-enhanced T1-weighted MR
images before therapy and corresponding scatter plots for quantification and distribution of ADC before and 3 weeks after
treatment initiation for the entire tumor volume. Unity and threshold designating significant change in ADC within the scat-
ter plot are presented by red and black lines, respectively. Voxels with significant increased, decreased, or unchanged ADC
values were assigned as red, blue, and green, respectively. Used with permission from Neoplasia Press. Galbán CJ, Mukherji
SK, Chenevert TL, et al. Parametric response map analysis of DW-MRI scans of head and neck cancer patients provides for
early detection of therapeutic efficacy. Transl Oncol 2009;2:184–190.).
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algorithms need to be used for image registration of
interval image examinations.
Cervical Cancer
In patients suffering from cervical cancer, DW-MRI
has already been performed for treatment monitoring
in patients undergoing chemotherapy. In a study of 20
patients suffering from cervical cancer, MRI was per-
formed before treatment, 2 weeks after initiation of ra-
dio- and chemotherapy, and at the end of therapy and
results were correlated with the change in tumor size
in MRI and conventional clinical response (45). In this
prospective study performed on a 1.5T MR unit, corre-
lation between change in ADC after 14 days of therapy
and tumor size evaluated by conventional MRI was
shown. Therefore, DW-MRI has the potential to pro-
vide the surrogate marker of treatment response in
advanced cervical cancers. The use of ADC offers an
early and reproducible indication of tumor response
which may ultimately allow the development of indi-
vidual treatment regimens. Similar results have been
described in a study performed in 47 patients with
cervical cancer undergoing chemoradiation therapy
compared with 26 normal controls. Response to treat-
ment was evaluated if no tumor was visible 3 to 6
months after completion of therapy. In patients with
squamous cell carcinomas, the 90th percentile of ADC
values was lower in responders than nonresponders (P
< 0.05). The median ADC in cervix carcinoma was sig-
nificantly lower compared with normal cervix, whereas
the ADC may have predictive value in squamous cell
tumors, but further long-term study will determine the
ultimate clinical utility of this technique (64).
Rectal Cancer
In rectal cancer, DW-MRI was performed for predic-
tion of response to chemoradiation. Pretreatment ADC
values in rectal cancer patients were found to be neg-
atively correlated with response: the presence of
higher pretreatment ADC values reflected necrotic
tumors that were resistant to therapy (43). The ADC
values following treatment were consistently lower
than before treatment, which was attributed to possi-
ble increase in fibrosis and scar tissue formation in
response to treatment. Similar results were observed
in another study performed on rectal cancer (64).
CONCLUSION
Changes in tumor volume are currently the clinical
response metric used for assessing response of a wide
variety of tumor types which must be done late in the
time course of treatment. DW-MRI has been shown to
be able to detect microstructural changes that precede
changes in tumor size. The effects of treatment can be
variable: necrosis as potential effect of treatment can
be detected as a decrease in perfusion reflecting a
decrease in the perfusion fraction (when performing
biexponential fitting) as well as an increase in diffu-
sion corresponding to an increase in the true diffusion
coefficient. Fibrosis as another potential treatment
response can be reflected in a decrease in perfusion
(corresponding to decrease in the perfusion fraction
Fp) as well as a decrease in diffusion corresponding to
an ADC decrease. These findings can also be eval-
uated by visual analysis of the corresponding high b-
value images as well as the ADC map.
For monitoring disease in most tumors and treat-
ment strategies an increased ADC value during treat-
ment corresponds to response, whereas predicting the
outcome of response is in most cases correlated with
a low pretreatment ADC value showing favorable
outcome in most tumors and with most treatment
options. However, in rectum carcinoma, a decrease in
ADC during treatment corresponded to response due
to fibrosis and scar tissue formation. Whereas pre-
dicting outcome also depends on the underlying ther-
apy, high pretreatment ADC values have been shown
to better correlate with the outcome in tumors treated
by vascular targeting agents (65).
DW-MRI has significant potential to be applied as
an imaging biomarker of treatment response at an
early time interval following treatment initiation. DW-
MRI protocols and analyses have to be standardized
and need to be tailored to individual tumor types and
anatomic sites and therapies. The time point of maxi-
mal response has to be evaluated for different tumors
and treatment strategies. DW-MRI as ultimate surro-
gate tumor marker has to be confirmed by compari-
son to progression-free survival and overall survival.
Therefore, multicenter studies to confirm these prom-
ising results are warranted.
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